Balance. Accordingly the main operations of the Company at present are business development and capital attraction. The Company has been in discussions with multiple strategic investors to fund internal product development, as well as with third parties who are interested in developing novel therapeutics that target the NETosis pathway.
While these discussions have been encouraging, they have been tempered by the current
macroeconomic trends that are impacting deal-making globally.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.731M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 56 | 154590723 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 55843936 | 26 |
View Market Depth
| Last trade - 16.26pm 29/07/2025 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable